Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects

Cancer Research

Volumn 74, Issue 24, 2014, Pages 7475-7486

  Chan, C T ^a,b   Qi, J ^c   Smith, W ^c   Paranol, R ^c   Mazitschek, R ^d,e,f   West, N ^c   Reeves, R ^a,b   Chiosis, G ^g   Schreiber, S L ^f   Bradner, J E ^c,d,f   Paulmurugan, R ^a,b   Gambhir, S S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLUORODEOXYGLUCOSE F 18; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HYDRAZONE DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; KETONE; METHYL 3 [4 [2 (2 BROMO 3 PHENYLALLYLIDENE)HYDRAZINECARBONYL]PHENYL]PROPANOATE; PROTEIN P23; UNCLASSIFIED DRUG; CINNAMIC ACID; CINNAMIC ACID DERIVATIVE; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE MARROW CELL; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; EX VIVO STUDY; FEMALE; GLUCOSE METABOLISM; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT; ACETYLATION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; MULTIMODAL IMAGING; SYNTHESIS; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CINNAMATES; FLUORODEOXYGLUCOSE F18; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICE; MOLECULAR IMAGING; MULTIMODAL IMAGING; MYELOID CELLS;

EID: 84918530742     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0197     Document Type: Article

References (49)

1. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009;107:600-8.
2. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang S-W. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 2010;10:935-54.
3. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238-43.
4. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
5. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.
6. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011;226:2378-90.
7. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 2012;14:215-21.
8. Horwitz SM. The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas. Curr Hematol Malig Rep 2011;6:67-72.
9. Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks K-M, et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 2011;71:3603-15.
10. Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 2012; 30:2303-17.
11. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011;7:263-83.
12. Mahboobi S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, et al. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR),human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J Med Chem 2010;53:8546-55.
13. Marcaurelle LA, Comer E, Dandapani S, Duvall JR, Gerard B, Kesavan S, et al. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc 2010;132:16962-76.
14. Mwakwari SC, Guerrant W, Patil V, Khan SI, Tekwani BL, Gurard-Levin ZA, et al. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J Med Chem 2010;53:6100-11.
15. Park H, Kim S, Kim YE, Lim SJ. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups. ChemMedChem 2010;5:591-7.
16. Petrella A, Fontanella B, Carratu A, Bizzarro V, Rodriquez M, Parente L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini Rev Med Chem 2011;11:519-27.
17. Zhang Y, Feng J, Jia Y, Wang X, Zhang L, Liu C, et al. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. J Med Chem 2011;54:2823-38.
18. Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol 2009;23:1963-72.
19. Meng Q, Chen X, Sun L, Zhao C, Sui G, Cai L. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90. Mol Cell Biochem 2011;348:165-71.
20. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, et al. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008; 112:1886-93.
21. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011;2011:875824.
22. Basak S, Pookot D, Noonan EJ, Dahiya R. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther 2008;7:3195-202.
23. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-7.
24. Chan CT, Paulmurugan R, Gheysens OS, Kim J, Chiosis G, Gambhir SS. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res 2008;68:216-26.
25. Chan CT, Reeves RE, Geller R, Yaghoubi SS, Hoehne A, Solow-Cordero DE, et al. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. Proc Natl Acad Sci 2012;109:E2476-E85.
26. Chiosis G, Caldas Lopes E, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 2006;7:534-41.
27. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. 2006;49:381-90.
28. Zhou V, Han S, Brinker A, Klock H, Caldwell J, Gu X-j. A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal Biochem 2004;331:349-57.
29. Loening AM, Fenn TD, Wu AM, Gambhir SS. Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng Des Sel 2006;19:391-400.
30. Yamaki H, Nakajima M, Shimotohno KW, Tanaka N. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. J Antibiot 2011;64:635-44.
31. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 2009;284:7436-45.
32. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci 2003; 100:4389-94.
33. Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc 2003;125:5586-7.
34. Barua S, Rege K. The influence of mediators of intracellular trafficking on transgene expression efficacy of polymer-plasmidDNAcomplexes. Biomaterials 2010;31:5894-902.
35. Chen S, Owens GC, Makarenkova H, Edelman DB. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS ONE [Electronic Resource] 2010;5:e10848.
36. Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 2009;284:17102-9.
37. Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A 2010;107:20003-8.
38. Zilberman Y, Ballestrem C, Carramusa L, Mazitschek R, Khochbin S, Bershadsky A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci 2009;122:3531-41.
39. Bieliauskas AV, Weerasinghe SVW, Pflum MKH. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg Med Chem Lett 2007;17:2216-9.
40. Suzuki T, Miyata N. Non-hydroxamate histone deacetylase inhibitors. Curr Med Chem 2005;12:2867-80.
41. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A 2002; 99:377-82.
42. Santos-Oliveira R, Antunes LJ. Radiopharmaceutical research and production in Brazil: A 30-year history of participation in the nuclear medicine scenario. J Nucl Med Technol 2011;39:237-9.
43. Wiant D, Gersh JA, Bennett M, Bourland JD. Evaluation of the spatial dependence of the point spread function in 2D PET image reconstruction using LOR-OSEM. Med Phys 2010;37:1169-82.
44. Duch J, Fuster D, Muñoz M, Fernández P, Paredes P, Fontanillas M, et al. F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009; 36:1551-7.
45. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50:21S-30S.
46. Middendorp M, Maute L, Sauter B, Vogl T, Grünwald F. Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med 2010;24:441-6.
47. Hendricks JA, Keliher EJ, Marinelli B, Reiner T, Weissleder R, Mazitschek R. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). J Med Chem 2011;54:5576-82.
48. Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res 2006;66:7621-9.
49. Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, et al. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Cancer Chemother Pharmacol 2011;68:389-98.